

**PALM INTRANET**

Day : Tuesday
Date: 6/1/2004
Time: 15:37:26

Inventor Name Search

Enter the first few letters of the Inventor's Last Name.
Additionally, enter the first few letters of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

side by
side

Count **Name**
result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES;
OP=AND

<u>L3</u>	L2 and (((non-neuronal or breast or lung or colon or pancreatic or prostate) adj cancer) or melanoma or mesothlioma)	3	<u>L3</u>
<u>L2</u>	(HSV adj 1716)	5	<u>L2</u>
<u>L1</u>	Brown-susanne-M\$.in.	13	<u>L1</u>

END OF SEARCH HISTORY

Status: Path 1 of [Dialog Information Services via Modem]

Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)
Trying 31060000009999...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

***** HHHHHHHH SSSSSSSS?

Status: Signing onto Dialog

ENTER PASSWORD:

***** HHHHHHHH SSSSSSSS? *****

Welcome to DIALOG

Status: Connected

Dialog level 04.09.00D

Last logoff: 25may04 13:24:04

Logon file001 01jun04 14:58:29

*** ANNOUNCEMENT ***

--File 654 - US published applications from March 15, 2001 to the present are now online. Please see HELP NEWS 654 for details.

--File 581 - The 2003 annual reload of Population Demographics is complete. Please see Help News581 for details.

--File 990 - NewsRoom now contains February 2004 to current records.
File 992 - NewsRoom 2003 archive has been newly created and contains records from January 2003. The oldest months's records roll out of File 990 and into File 992 on the first weekend of each month.
To search all 2003 records BEGIN 990, 992, or B NEWS2003, a new OneSearch category.

--Connect Time joins DialUnits as pricing options on Dialog.
See HELP CONNECT for information.

--SourceOne patents are now delivered to your email inbox as PDF replacing TIFF delivery. See HELP SOURCE1 for more information.

--Important Notice to Freelance Authors--
See HELP FREELANCE for more information

NEW FILES RELEASED

***MetalBase (File 36)

***AeroBase (File 104)

***DIOGENES: Adverse Drug Events Database (File 181)

***World News Connection (File 985)

***Dialog NewsRoom - 2003 Archive (File 992)

***TRADEMARKSCAN-Czech Republic (File 680)

***TRADEMARKSCAN-Hungary (File 681)

***TRADEMARKSCAN-Poland (File 682)

UPDATING RESUMED

RELOADED

***Toxfile (File 156)

***Medline (Files 154-155)

***Population Demographics -(File 581)

***CLAIMS Citation (Files 220-222)

REMOVED

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
>>> of new databases, price changes, etc. <<<

KWIC is set to 50.

HIGHLIGHT set on as '*'

* ALL NEW CURRENT YEAR RANGES HAVE BEEN * * *

* * * INSTALLED * * *

*

File 1:ERIC 1966-2004/May 24

(c) format only 2004 The Dialog Corporation

Set	Items	Description
-----	-------	-------------

---	-----	-----
-----	-------	-------

Cost is in DialUnits

?b 155, 159, 5, 73

01jun04 14:58:40 User259876 Session D628.1

\$0.32 0.092 DialUnits File1

\$0.32 Estimated cost File1

\$0.05 TELNET

\$0.37 Estimated cost this search

\$0.37 Estimated total session cost 0.092 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1966-2004/May W4

(c) format only 2004 The Dialog Corp.

***File 155: Medline has been reloaded. Accession numbers**

have changed. Please see HELP NEWS 154 for details.

File 159:Cancerlit 1975-2002/Oct

(c) format only 2002 Dialog Corporation

***File 159: Cancerlit ceases updating with immediate effect.**

Please see HELP NEWS.

File 5:Biosis Previews(R) 1969-2004/May W4

(c) 2004 BIOSIS

File 73:EMBASE 1974-2004/May W4

(c) 2004 Elsevier Science B.V.

Set	Items	Description
-----	-------	-------------

---	-----	-----
-----	-------	-------

?s (HSV (w) 1716)

42675 HSV

583 1716

S1 35 (HSV (W) 1716)

?s s1 and (((non-neuronal or breast or lung or colon or pancreatic or prostate) (w) cancer) or melanoma or mesothelioma)

35 S1

15 NON-NEURONAL

618909 BREAST

1135427 LUNG

303301 COLON

298956 PANCREATIC

226515 PROSTATE

2405400 CANCER

656978 (((((NON-NEURONAL OR BREAST) OR LUNG) OR COLON) OR
PANCREATIC) OR PROSTATE) (W)CANCER

202097 MELANOMA

27414 MESOTHELIOMA

S2 22 S1 AND (((NON-NEURONAL OR BREAST OR LUNG OR COLON OR
PANCREATIC OR PROSTATE) (W) CANCER) OR MELANOMA OR
MESOTHELIOMA)

?rd

...completed examining records

S3 8 RD (unique items)

?t_s3/3,k/all

3/3,K/1 (Item 1 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

13496994 PMID: 9182825

Treatment of experimental subcutaneous human *melanoma* with a replication-restricted herpes simplex virus mutant.

Randazzo B P; Bhat M G; Kesari S; Fraser N W; Brown S M
The Wistar Institute, Department of Dermatology, University of Pennsylvania Medical System, Philadelphia 19104, USA.
Journal of investigative dermatology (UNITED STATES) Jun 1997, 108 (6) p933-7, ISSN 0022-202X Journal Code: 0426720
Contract/Grant No.: 1K08CA65839; CA; NCI
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Treatment of experimental subcutaneous human *melanoma* with a replication-restricted herpes simplex virus mutant.

Modified, non-neurovirulent herpes simplex viruses (HSV) have shown promise for the treatment of brain tumors, including intracranial *melanoma*. In this report, we show that *HSV*-1716*, an HSV-1 mutant lacking both copies of the gene coding-infected cell protein 34.5 (ICP 34.5), can effectively treat experimental subcutaneous human *melanoma* in mice. In vitro, *HSV*-1716* replicated in all 26 human *melanoma* cell lines tested, efficiently lysing the cells. Therapeutic infection of subcutaneous human *melanoma* nodules with *HSV*-1716* led to viral replication that was restricted to tumor cells by immunohistochemistry. Moreover, *HSV*-1716* treatment significantly inhibited progression of preformed subcutaneous human *melanoma* nodules in SCID mice and caused complete regression of some tumors. This work expands the potential scope of HSV-1-based cancer therapy.

Descriptors: Herpesvirus 1, Human--genetics--GE; *Herpesvirus 1, Human--physiology--PH; **Melanoma*--therapy--TH; *Mutation; *Skin Neoplasms--therapy--TH...; AN; Cell Death--physiology--PH; DNA, Viral--analysis--AN; DNA, Viral--chemistry--CH; DNA, Viral--genetics--GE; Herpesvirus 1, Human--isolation and purification--IP; Immunohistochemistry; *Melanoma*--pathology--PA; *Melanoma*--virology--VI; Mice; Mice, SCID; Neoplasm Regression, Spontaneous--pathology--PA; Neoplasm Transplantation; Skin Neoplasms--pathology--PA; Skin Neoplasms--virology--VI; Tumor Cells, Cultured; Virus Replication

3/3,K/2 (Item 2 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

13339139 PMID: 9012475

Use of a "replication-restricted" herpes virus to treat experimental human malignant *mesothelioma*.

Kucharczuk J C; Randazzo B; Chang M Y; Amin K M; Elshami A A; Sterman D H; Rizk N P; Molnar-Kimber K L; Brown S M; MacLean A R; Litzky L A; Fraser N W; Albelda S M; Kaiser L R

Thoracic Oncology Research Laboratory, University of Pennsylvania Medical Center, Philadelphia 19104, USA.

Cancer research (UNITED STATES) Feb 1 1997, 57 (3) p466-71, ISSN 0008-5472 Journal Code: 2984705R

Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Use of a "replication-restricted" herpes virus to treat experimental human malignant *mesothelioma*.

...in the treatment of brain tumors. However, HSV-1 can infect and lyse a wide range of cell types. In this report, we show that *HSV*-1716*, a mutant lacking both copies of the gene coding ICP-34.5, can effectively treat a localized i.p. malignancy. Human malignant *mesothelioma* cells supported the growth of *HSV*-1716* and were efficiently lysed in vitro. i.p. injection of *HSV*-1716* into animals with established tumor nodules reduced tumor burden and significantly prolonged survival in an animal model of non-central nervous system-localized human malignancy...

... human tumors. These findings suggest that this virus may be efficacious and safe for use in localized human malignancies of nonneuronal origin such as malignant *mesothelioma*.

Descriptors: Gene Therapy; **Mesothelioma*--therapy--TH; *Simplexvirus--genetics--GE; *Viral Proteins--genetics--GE; *Virus Replication

3/3,K/3 (Item 3 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

11187284 PMID: 11229673

Intralesional injection of herpes simplex virus 1716 in metastatic *melanoma*.

MacKie R M; Stewart B; Brown S M
Lancet (England) Feb 17 2001, 357 (9255) p525-6, ISSN 0140-6736
Journal Code: 2985213R
Document type: Clinical Trial; Letter
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Intralesional injection of herpes simplex virus 1716 in metastatic *melanoma*.

We have previously shown that avirulent but replication-competent herpes simplex virus (*HSV*) 1716* causes cell death in human *melanoma* cell lines in vitro and selectively replicates in *melanoma* tissue in nude mice. We now present a pilot study of intratumoral injection of HSV1716 into subcutaneous nodules of metastatic *melanoma* in five patients with stage 4 *melanoma*. Two patients each received one injection, two received two injections, and one received four injections of 10(3) plaque-forming units HSV1716. In one patient...

... of virus replication confined to tumour cells. These findings suggest that HSV1716 is non-toxic and could be of therapeutic benefit in patients with metastatic *melanoma*.

Descriptors: Biological Therapy; **Melanoma*--therapy--TH; *Simplexvirus--physiology--PH; *Melanoma*--secondary--SC; Pilot Projects; Simplexvirus--genetics--GE; Viral Proteins--genetics--GE; Virus Replication

3/3,K/4 (Item 4 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

10509234 PMID: 10609661

Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (*HSV*-1716*) in human non-small cell *lung* *cancer*.

Toyoizumi T; Mick R; Abbas A E; Kang E H; Kaiser L R; Molnar-Kimber K L
Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.

Human gene therapy (UNITED STATES) Dec 10 1999, 10 (18) p3013-29,
ISSN 1043-0342 Journal Code: 9008950

Contract/Grant No.: CA16520-24; CA; NCI; CA66727-S1; CA; NCI
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (*HSV*-1716*) in human non-small cell *lung* *cancer*.

A replication-selective herpes simplex virus type 1 ICP34.5 mutant (*HSV*-1716*) has shown efficacy both in vitro and in vivo against human non-small cell *lung* *cancer* (NSCLC) cell lines but complete eradication of tumor has not been accomplished with a single viral treatment in our murine xenograft models. Therefore, strategies to enhance the efficacy of this treatment were investigated. We determined the oncolytic activity of *HSV*-1716* in NCI-H460 cells in combination with each of four chemotherapeutic agents: mitomycin C (MMC), cis-platinum II (cis-DDP), methotrexate (MTX), or doxorubicin (ADR). Isobologram analysis was performed to evaluate the interaction between the viral and chemotherapeutic agents. The oncolytic effect of *HSV*-1716* in combination with MMC was synergistic in two of five NSCLC cell lines. In the other three cell lines, the combined effect appeared additive. No...

... was observed. The in vivo effect of this combination was then examined in a murine xenograft model. NCI-H460 flank tumors were directly injected with *HSV*-1716* (4 x 10⁶ PFU) followed by intravenous MMC administration (0.17 mg/kg) 24 hr later. After 3 weeks, the mean tumor weight in the...

... was significantly less than either individual treatment in an additive manner. The synergistic dose of MMC neither augmented nor inhibited viral replication in vitro and *HSV*-1716* infection did not upregulate DT-diaphorase, which is the primary enzyme responsible for MMC activation. In summary, the combination of *HSV*-1716* with common chemotherapeutic agents may augment the effect of HSV-based therapy in the treatment of NSCLC.

3/3,K/5 (Item 5 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

10484242 PMID: 10585055

Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system.

Lambright E S; Caparrelli D J; Abbas A E; Toyoizumi T; Coukos G; Molnar-Kimber K L; Kaiser L R

Harrison Department of Surgical Research, University of Pennsylvania Medical Center, Philadelphia, USA.

Annals of thoracic surgery (UNITED STATES) Nov 1999, 68 (5) p1756-60; discussion 1761-2, ISSN 0003-4975 Journal Code: 15030100R

Contract/Grant No.: PO-66726-S1; PHS

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

BACKGROUND: Herpes simplex virus (*HSV*)-1716*, a replication-restricted herpes simplex virus type 1, has shown efficacy as an oncolytic treatment for central nervous system tumors, *breast* *cancer*, ovarian cancer, and malignant *mesothelioma*. We evaluated the efficacy of *HSV*-1716* in a murine *lung* *cancer* model, Lewis lung carcinoma. **METHODS:** Lewis lung carcinoma cells were infected with *HSV*-1716* and implanted in the flanks of mice at varying ratios of infected to uninfected cells. Tumor burden was assessed by measurement of the weight of...

... to-uninfected) cells completely prevented tumor formation and ratio of 1:100 suppressed tumor growth. Established tumors at a distant site in the groups receiving *HSV*-1716* infected cells showed no difference in size versus control, suggesting absence of a vaccine effect. **CONCLUSIONS:** We conclude that *HSV*-1716* may provide a oncolytic therapy for *lung* *cancer* even in the absence of immune system induction and a "carrier" cell could potentially deliver this vector.

3/3,K/6 (Item 1 from file: 159)
DIALOG(R)File 159:Cancerlit
(c) format only 2002 Dialog Corporation. All rts. reserv.

02322796 PMID: 97604982

Replication-restricted herpes simplex virus-based treatment of localized non CNS malignancy (Meeting abstract).

Kucharczuk; Randazzo; Elshami; Sterman; Rizk; Brown; Molnar-Kimber; Litzky; Fraser; Kaiser; Albelda

Thoracic Oncology Lab., Univ. of Pennsylvania Medical Center, Philadelphia, PA 19104

Proc Annu Meet Am Assoc Cancer Res 1996, 37, ISSN 0197-016X

Document Type: MEETING ABSTRACTS

Languages: ENGLISH

Main Citation Owner: NOTNLM

Record type: Completed

...brain tumors. However, HSV-1 can infect and lyse a wide range of other cell types. The purpose of this study was to determine if *HSV*-1716*, a mutant lacking both copies of the gamma-34.5 gene, could effectively treat localized intraperitoneal malignancy. Human malignant *mesothelioma* cells supported the growth of *HSV*-1716* and were rapidly lysed in vitro. Intraperitoneal injection of *HSV*-1716* into animals with established *mesothelioma* tumor nodules reduced tumor burden and significantly prolonged survival in an animal model of non-CNS localized human malignancy. Importantly, the *HSV*-1716* mutant was 'replication-restricted' to malignant cells, in that it did not disseminate or persist after intraperitoneal injection into SCID mice bearing human tumors. These...

... that the replication-restricted HSV mutant 1716 may be efficacious and safe for use in localized human malignancies of non-neuronal origin such as malignant *mesothelioma*, brain cancer, ovarian carcinoma, or bladder cancer.)

3/3,K/7 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0011875509 BIOSIS NO.: 199900135169

Combination therapy with herpes simplex virus type 1 ICP34.5 mutant (*HSV*-1716*) and common chemotherapeutic agents for human non-small cell *lung* *cancer* (NSCLC)

AUTHOR: Toyozumi Takane (Reprint); Abbas Abbas E (Reprint); Caparrelli David J (Reprint); Kang Eugene H (Reprint); Albelda Steven M; Kaiser Larry R (Reprint); Molnar-Kimber Katherine L (Reprint)

AUTHOR ADDRESS: Dep. Surg., Univ. Pa. Sch. Med., Philadelphia, PA, USA**USA

JOURNAL: Cancer Gene Therapy 5 (6 CONF. SUPPL.): pS7-S8 Nov.-Dec., 1998
1998

MEDIUM: print

CONFERENCE/MEETING: Seventh International Conference on Gene Therapy of Cancer San Diego, California, USA November 19-21, 1998; 19981119

ISSN: 0929-1903

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Citation

LANGUAGE: English

Combination therapy with herpes simplex virus type 1 ICP34.5 mutant (*HSV*-1716*) and common chemotherapeutic agents for human non-small cell *lung* *cancer* (NSCLC)

DESCRIPTORS:

...ORGANISMS: human non-small cell *lung* *cancer*

3/3,K/8 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

12248895 EMBASE No: 2003361075

Comparison of replication-selective, oncolytic viruses for the treatment of human cancers

Wildner O.
O. Wildner, Ruhr-Universitat Bochum, Abteilung fur Molek./Med. Virologie,
D-44801 Bochum Germany
AUTHOR EMAIL: Oliver.Wildner@ruhr-uni-bochum.de
Current Opinion in Molecular Therapeutics (CURR. OPIN. MOL. THER.) (United Kingdom) 2003, 5/4 (351-361)
CODEN: CUOTF ISSN: 1464-8431
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 147

BRAND NAME/MANUFACTURER NAME: ONYX 015/Onyx; *HSV* *1716*/Crusade Laboratories; g 207/Medigene; pv 701/Wellstat Biologics; nv 1020; mth 68
MEDICAL DESCRIPTORS:

...deletion; tumor cell; virus infection; Adenovirus; virus capsid; virus envelope; cancer combination chemotherapy; antineoplastic activity; gene expression; immune response; virus inactivation; suicide gene; virus mutant ; *melanoma*--drug therapy--dt; ovary cancer--drug therapy--dt; head and neck cancer--drug therapy--dt; Herpes simplex virus 1; encephalitis--side effect--si; glioblastoma--drug...

DRUG TERMS (UNCONTROLLED): *HSV* *1716*--adverse drug reaction--ae; *HSV* *1716*--clinical trial--ct; *HSV* *1716*--drug therapy--dt; *HSV* *1716*--pharmaceutics--pr; *HSV* *1716*--pharmacology--pd; *HSV* *1716*--intratumoral drug administration--tu; g 207--adverse drug reaction--ae; g 207--drug therapy--dt; g 207--pharmaceutics--pr; g 207--pharmacology--pd; g 207...

?ds

Set	Items	Description
S1	35	(HSV (W) 1716)
S2	22	S1 AND (((NON-NEURONAL OR BREAST OR LUNG OR COLON OR PANCREATIC OR PROSTATE) (W) CANCER) OR MELANOMA OR MESOTHELIOMA)
S3	8	RD (unique items)
?s s1 same (cancer or tumor or tumour or neoplastic)		
>>>Term "SAME" in invalid position		
?s s1 (s) (cancer or tumor or tumour or neoplastic)		
	35	S1
	2405400	CANCER
	2419065	TUMOR
	286689	TUMOUR
	663056	NEOPLASTIC
S4	30	S1 (S) (CANCER OR TUMOR OR TUMOUR OR NEOPLASTIC)
?s s4 not s2		
	30	S4
	22	S2
S5	9	S4 NOT S2
?rd		
...completed examining records		
S6	3	RD (unique items)
?t s6/3,k/all		

6/3,K/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

14393061 PMID: 10389942

Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer.

Coukos G; Makrigiannakis A; Kang E H; Caparelli D; Benjamin I; Kaiser L R

; Rubin S C; Albelda S M; Molnar-Kimber K L

Department of Obstetrics and Gynecology, University of Pennsylvania Medical Center, Philadelphia 19104, USA.

Clinical cancer research - an official journal of the American Association for Cancer Research (UNITED STATES) Jun 1999, 5 (6) p1523-37, ISSN 1078-0432 Journal Code: 9502500

Contract/Grant No.: PO-66726-S1; PHS

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... 1 (HSV-1) used as an oncolytic agent against EOC and the use of human teratocarcinoma PA-1 as carrier cells for i.p. therapy. *HSV*-1716*, a replication-competent attenuated strain lacking ICP34.5, caused a direct dose-dependent oncolytic effect on EOC cells in vitro. A single i.p. administration of 5×10^6 plaque-forming units resulted in a significant reduction of *tumor* volume and *tumor* spread and an increase in survival in a mouse xenograft model. PA-1 cells supported HSV replication in vitro and bound preferentially to human ovarian carcinoma surfaces compared with mesothelial surfaces in vitro and in vivo. In comparison with the administration of *HSV*-1716* alone, irradiated PA-1 cells, infected at two multiplicities of infection with *HSV*-1716* and injected i.p. at 5×10^6 cells/animal, led to a significant *tumor* reduction in the two models tested and the significant prolongation of mean survival in one model. Histological evaluation revealed extensive necrosis in *tumor* areas infected by *HSV*-1716*. Immunohistochemistry against HSV-1 revealed areas of viral infection within *tumor* nodules, which persisted for several weeks after treatment. Administration of HSV-infected PA-1 carrier cells resulted in larger areas of *tumor* infected by the virus. Our results indicate that replication-competent attenuated HSV-1 exerts a potent oncolytic effect on EOC, which may be further enhanced...

... the utilization of a delivery system with carrier cells, based on amplification of the viral load and possibly on preferential binding of carrier cells to *tumor* surfaces.

6/3,K/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

13706898 PMID: 9400985

Herpes simplex virus 1716, an ICP 34.5 null mutant, is unable to replicate in CV-1 cells due to a translational block that can be overcome by coinfection with SV40.

Randazzo B P; Tal-Singer R; Zabolotny J M; Kesari S; Fraser N W

The Wistar Institute, Philadelphia, PA 19104, USA.

Journal of general virology (ENGLAND) Dec 1997, 78 (Pt 12) p3333-9, ISSN 0022-1317 Journal Code: 0077340

Contract/Grant No.: 1K08CA65839; CA; NCI; NS33768; NS; NINDS

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... RNA-activated protein kinase (PKR)-dependent translational block that normally occurs during virus infection. We now report that an HSV ICP 34.5 mutant called *HSV*-1716* is unable to replicate in the simian kidney cell-derived line CV-1, due to a translational block. Moreover, we find that this block can be overcome by simian virus 40 (SV40). This has been shown directly by infecting CV-1 cells with SV40 and *HSV*-1716* simultaneously, and indirectly via *HSV*-1716* infection of COS-1 cells (CV-1 cells transformed by an origin-defective mutant of SV40 that codes for wild-type T antigen). The translational...

6/3,K/3 (Item 3 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

10886811 PMID: 11020355

Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model.

Lambright E S; Kang E H; Force S; Lanuti M; Caparrelli D; Kaiser L R; Albelda S M; Molnar-Kimber K L

Thoracic Oncology Research Laboratory, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA.

Molecular therapy - the journal of the American Society of Gene Therapy (UNITED STATES) Oct 2000, 2 (4) p387-93, ISSN 1525-0016

Journal Code: 100890581

Contract/Grant No.: P50-CA-83638; CA; NCI; P01-CA66726; CA; NCI; R01-74958; PHS

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... of the human population has been previously exposed to herpes simplex virus, the efficacy of HSV-based oncolytic therapy was investigated in an immunocompetent animal *tumor* model. EJ-6-2-Bam-6a, a *tumor* cell line derived from h-ras-transformed murine fibroblast, exhibit a diffuse growth pattern in the peritoneal cavity of BALB/c mice and replicate *HSV*-1716* to titers observed in human tumors. An established intraperitoneal (ip) *tumor* model of EJ-6-2-Bam-6a in naive and HSV-immunized mice was used to evaluate the efficacy of single or multiple ip administrations of *HSV*-1716* (4 x 10(6) pfu/treatment) or of carrier cells, which are irradiated, ex vivo virally infected EJ-6-2-Bam-6a cells that can...

...multiply treated, HSV-naive animals. Prior immunization of the mice with HSV did not significantly decrease the median survival of the single or multiply treated *HSV*-1716* or the carrier cell-treated groups. These studies support the development of replication-selective herpes virus mutants for use in localized intraperitoneal malignancies.

?ds

Set	Items	Description
S1	35	(HSV (W) 1716)
S2	22	S1 AND (((NON-NEURONAL OR BREAST OR LUNG OR COLON OR PANCREATIC OR PROSTATE) (W) CANCER) OR MELANOMA OR MESOTHELIOMA)
S3	8	RD (unique items)
S4	30	S1 (S) (CANCER OR TUMOR OR TUMOUR OR NEOPLASTIC)
S5	9	S4 NOT S2
S6	3	RD (unique items)

?logoff

01jun04 15:03:47 User259876 Session D628.2

\$1.67	0.521 DialUnits	File155
\$1.68	8 Type(s) in Format	3
\$1.68	8 Types	
\$3.35	Estimated cost	File155
\$1.09	0.368 DialUnits	File159
\$0.26	1 Type(s) in Format	3
\$0.26	1 Types	
\$1.35	Estimated cost	File159
\$2.78	0.497 DialUnits	File5
\$1.75	1 Type(s) in Format	3
\$1.75	1 Types	
\$4.53	Estimated cost	File5
\$4.70	0.479 DialUnits	File73
\$2.70	1 Type(s) in Format	3
\$2.70	1 Types	
\$7.40	Estimated cost	File73
	OneSearch, 4 files,	1.866 DialUnits FileOS
\$1.50	TELNET	

\$18.13 Estimated cost this search
\$18.50 Estimated total session cost 1.958 DialUnits

Status: Signed Off. (6 minutes)